ESMO Congress 2026

The focal point of this material is Guardant Health's liquid biopsy data at #ESMO26. Regarding the established evidence base for this asset class, one point must be made first: the accompanying background materials address patient shared decision-making and quality-of-life preferences ^[1], family caregivers' roles in treatment decision-making ^[3], a retrospective analysis of baseline immunoglobulins and outcomes in CLL ^[4], prognostic nomograms for thyroid cancer ^[2], the pandemic's impact on oncology care in Manitoba ^[5], and a text-message psychological support program ^[6] — none of which involves ctDNA liquid biopsy or MRD, and none offers published pivotal trials in lung, colorectal, or gastric cancer for reference. The evidence base for this class therefore cannot be confirmed within this material (to be confirmed).

The live post discloses the following meeting news: Guardant Health, together with research collaborators, will present 25 abstracts at #ESMO26, including 5 rapid oral presentations, exploring advances in liquid biopsy across lung, colorectal, and gastric cancers; the topics span MRD surveillance, treatment response, and resistance research, with emphasis on how genomic and epigenomic insights can inform cancer care. The company also notes that these findings rest on its biopharma, academic, and public-private partnerships. Specific abstract titles, trial designs, sample sizes, and assay performance figures are not disclosed. A second post in the same thread comes from TargetedOnc, announcing that Dr. Jaspreet Grewal (Norton Health) is taking over its account that day to share live meeting highlights — this is a media arrangement, not a data readout, and should be viewed only as an information channel.

As for the step forward relative to existing knowledge, by the post's own framing, the value of this batch lies in 'expanding the evidence across MRD surveillance, treatment response, and resistance research,' and in extending the interpretive framework from genomics alone to genomic plus epigenomic insights, covering three tumor types (lung, colorectal, gastric) and three settings (surveillance, response, resistance). Because the background materials provide no prior pivotal-trial facts in this field, no cross-trial comparison is possible within this material; it is best read as a concentrated showcase of evidence breadth and partnership network rather than a single-readout event.

The limitations are equally clear: the post gives only the number of abstracts (25) and rapid oral presentations (5), with no specific efficacy or performance figures, and trial names, endpoints, and populations are undisclosed; the TargetedOnc account takeover is merely a way of disseminating meeting content. A substantive assessment of these liquid biopsy data must wait until the abstracts and oral presentations are published in full.